Search Result

Results for "

S6K phosphorylation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Ribosomal S6 Kinase (RSK) (5) 5-HT Receptor (3) Akt (11) Aminopeptidase (2) AMPK (3) Amyloid-β (1) Androgen Receptor (2) Apoptosis (5) ATM/ATR (1) Autophagy (5) Bacterial (4) Bcl-2 Family (1) c-Myc (1) Cholinesterase (ChE) (1) Drug Derivative (1) EGFR (4) Enteropeptidase (2) Epigenetic Reader Domain (2) ERK (4) Ferroptosis (1) FOXO (2) Fungal (3) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (1) IKK (2) Insulin Receptor (1) Keap1-Nrf2 (1) mTOR (15) NF-κB (1) Notch (1) Opioid Receptor (2) p38 MAPK (1) PDK-1 (5) PI3K (2) PI5P4K (1) Pim (1) PTEN (1) Ras (1) Reference Standards (5) STAT (1) TGF-β Receptor (1) VEGFR (1) Wnt (1) γ-secretase (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (6) Metabolic Disease (7) Neurological Disease (7)

By Targets:

Ribosomal S6 Kinase (RSK) (5)

5-HT Receptor (3)

Akt (11)

Aminopeptidase (2)

AMPK (3)

Amyloid-β (1)

Androgen Receptor (2)

Apoptosis (5)

ATM/ATR (1)

Autophagy (5)

Bacterial (4)

Bcl-2 Family (1)

c-Myc (1)

Cholinesterase (ChE) (1)

Drug Derivative (1)

EGFR (4)

Enteropeptidase (2)

Epigenetic Reader Domain (2)

ERK (4)

Ferroptosis (1)

FOXO (2)

Fungal (3)

GSK-3 (1)

HIF/HIF Prolyl-Hydroxylase (1)

IKK (2)

Insulin Receptor (1)

Keap1-Nrf2 (1)

mTOR (15)

NF-κB (1)

Notch (1)

Opioid Receptor (2)

p38 MAPK (1)

PDK-1 (5)

PI3K (2)

PI5P4K (1)

Pim (1)

PTEN (1)

Ras (1)

Reference Standards (5)

STAT (1)

TGF-β Receptor (1)

VEGFR (1)

Wnt (1)

γ-secretase (1)

By Research Areas:

Cancer (30)

Cardiovascular Disease (1)

Infection (4)

Inflammation/Immunology (6)

Metabolic Disease (7)

Neurological Disease (7)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: Ribosomal S6 Kinase (RSK) Oxidative Phosphorylation DYRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10514

BX795 Maximum Cited Publications 38 Publications Verification	PDK-1 IKK Autophagy	Cancer
BX795 is a potent and selective inhibitor of PDK1, with an IC₅₀ of 6 nM. BX795 is also a potent and relatively specific inhibitor of TBK1 and IKKε, with an IC₅₀ of 6 and 41 nM, respectively. BX795 blocks phosphorylation of S6K1, Akt, PKCδ, and GSK3β, and has lower selectivity over PKA, PKC, c-Kit, GSK3β etc. BX795 modulates autophagy .

HY-13595

Chrysophanol Maximum Cited Publications 6 Publications Verification Chrysophanic acid	EGFR	Cancer
Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and *mTOR/p70S6K*.

HY-132168

RMC-5552 5 Publications Verification	mTOR	Cancer
RMC-5552 is a potent and selective mTORC1 inhibitor. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC₅₀s of 0.14 nM and 0.48 nM, respectively. RMC-5552 shows much lower pAKT inhibition (IC₅₀ of 19 nM), resulting in mTORC1/mTORC2 selectivity approaching 40-fold. RMC-5552 has anti-cancer activity .

HY-N0656A

(+)-Usnic acid 2 Publications Verification	mTOR Bacterial Autophagy	Infection Inflammation/Immunology Cancer
(+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of mTOR, and inhibits mTORC1/2 activity. (+)-Usnic acid inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer and anti-inflammatory activity. (+)-Usnic acid possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium .

HY-121629

PS210	PDK-1	Cancer
PS210 is a potent and selective PDK1 activator with a K_d of 3 μM and targets the PIF-binding pocket of PDK1. PS210 is inactive against other protein kinases, including PDK1 downstream signaling components such as S6K, PKB/Akt or GSK3. In cells, the prodrug of PS210 (PS423) acts as a substrate-selective inhibitor of PDK1, inhibiting the phosphorylation and activation of S6K .

HY-103100

SB-699551 1 Publications Verification	5-HT Receptor Epigenetic Reader Domain Akt Ribosomal S6 Kinase (RSK) FOXO	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
SB-699551 is a selective and brain penetrant 5-HT5A receptor antagonist with a pK_i of 8.2 nM. SB-699551 shows high selectivity over most other 5-HT receptor subtypes, dopamine receptors, and α1B adrenoceptor. SB-699551 disrupts Gαi/o-coupled and PI3K/AKT/mTOR signaling pathways, alters CREB, ATF1, AKT, PRAS40, S6K, and FOXO1 phosphorylation in breast tumor cells. SB-699551 can be used for the research of anxiety, breast cancer, and Alzheimer's disease .

HY-N1677

2,6-Dimethoxy-1,4-benzoquinone	Akt mTOR Bacterial Fungal AMPK	Infection Metabolic Disease Inflammation/Immunology Cancer
2,6-Dimethoxy-1,4-benzoquinone is a 1,4-benzoquinone derivative. 2,6-Dimethoxy-1,4-benzoquinone promotes phosphorylation of AKT, *S6K, mTOR, 4E-BP1, and AMPK, and attenuates mTORC1* activity as part of the AKT/mTOR pathway. 2,6-Dimethoxy-1,4-benzoquinone stimulates myoblast differentiation, increases myotube size, elevates MHC protein expression, enhances mitochondrial biogenesis, respiration, and DNA content, and increases skeletal muscle weights, fiber size, grip strength, and treadmill performance. 2,6-Dimethoxy-1,4-benzoquinone exerts anti-cancer, anti-inflammatory, anti-adipogenic, antibacterial, and antimutagenic effects, inhibits adipogenic transcription factors, nitric oxide production, skin tumor development, Magnaporthe oryzae growth, spore germination, appressorium formation, and growth of select bacterial species, induces H₂O₂ generation and rice defense gene expression, and reduces rice blast lesion formation. 2,6-Dimethoxy-1,4-benzoquinone can be used for the research of obesity, skin tumorigenesis, rice blast disease, and food-borne illness .

HY-139188

CC260	PI5P4K	Metabolic Disease Cancer
CC260 is a selective PI5P4Kα and PI5P4Kβ inhibitor with K_is of 40 nM and 30 nM, respectively. CC260 does not inhibit or weakly inhibits other protein kinases, such as Plk1 and RSK2. CC260 can be used for cell energy metabolism, diabetes and cancer research .

HY-N0008

Orcinol glucoside	Wnt p38 MAPK mTOR Keap1-Nrf2 TGF-β Receptor	Neurological Disease Metabolic Disease
Orcinol glucoside is an orally active, blood-brain barrier permeable osteoblast proliferation promoter that targets the Nrf2/Keap1, mTOR and p38 signaling pathways. Orcinol glucoside promotes Nrf2 nuclear translocation, upregulates antioxidant enzyme levels, enhances the phosphorylation of mTOR and *p70S6K, and inhibits the enzymatic activity of HAS2* as well as the nuclear translocation of GR. Orcinol glucoside also alleviates oxidative stress, inhibits autophagic flux, osteoclastogenesis and TGF-β1-induced M2 polarization, while reducing collagen deposition and effectively promoting the proliferation, differentiation and mineralization of osteoblasts. Orcinol glucoside also exhibits anti-pulmonary fibrosis, anxiolytic and antidepressant activities. Orcinol glucoside can be used in the research of senile and glucocorticoid-induced osteoporosis, idiopathic pulmonary fibrosis (IPF), anxiety and other related diseases .

HY-161275

BI-4732	EGFR Akt ERK Ribosomal S6 Kinase (RSK)	Cancer
BI-4732 is an orally active, reversible, ATP-competitive EGFR inhibitor with blood-brain barrier penetration. BI-4732 inhibits the kinase activity of EGFR L858R, T790M and C797S with IC₅₀ values of 1 nM while sparing EGFR wild-type. BI-4732 inhibits EGFR and reduces the phosphorylation of AKT, ERK, and *S6K. BI-4732 demonstrates excellent intracranial anti-tumor efficacy in YU-1097 xenograft model harboring EGFR*_E19del/T790M/C797S. BI-4732 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-N0597

Panaxatriol 3 Publications Verification	Others Insulin Receptor	Cardiovascular Disease Others Metabolic Disease Cancer
Panaxatriol is an orally active insulin sensitizer. Panaxatriol enhances the phosphorylation levels of Akt, insulin receptor and p70S6K in skeletal muscle. Panaxatriol reduces the mRNA expression level of Atrogin1 in skeletal muscle. Panaxatriol induces apoptosis, pre-G1 cell cycle arrest and increased intracellular ROS levels in prostate cancer cells, decreases mitochondrial membrane potential, inhibits cell migration and reduces colony formation. Panaxatriol can be used in research related to insulin resistance, myocardial ischemia/reperfusion injury and prostate cancer .

HY-134903

(32-Carbonyl)-RMC-5552	mTOR	Cancer
(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC₅₀s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2) .

HY-178042

SS-3091	Ras Akt ERK	Cancer
SS-3091 is a pan-KRas inhibitor active across KRas ^G12D, KRas ^G12C, KRas ^G12V, KRas ^G12S mutants, with minimal effects on non-KRas-driven cancer cells. SS-3091 binds to the KRas·ARaf interaction interface, destabilizes the complex, and attenuates KRas activity. SS-3091 suppresses phosphorylation of *S6K, Akt, and ERK. SS-3091 reduces proliferation and decreases colony formation of cancer cells bearing KRas* ^G12 mutations. SS-3091 can be used for the research of KRas-driven cancers .

HY-W348485

WRX606	mTOR	Cancer
WRX606 is an orally active nonrapalog inhibitor for mTOR complex 1 (mTORC1M). WRX606 inhibits the phosphorylation of mTORC1 substrate S6 kinase 1 (S6K1) (IC₅₀ = 10 nM) and eukaryotic translation initiation factor 4E binding protein (p-4E-BP1) (IC₅₀ = 0.27 μM) in MCF-7 cells. WRX606 suppresses tumor growth in mice without promotion of metastasis. WRX606 can be studied in research as an antitumor agent .

HY-N11709

Theasaponin E1	Apoptosis VEGFR ATM/ATR PTEN Akt mTOR HIF/HIF Prolyl-Hydroxylase NF-κB Notch Cholinesterase (ChE) Amyloid-β γ-secretase Ferroptosis Fungal	Infection Neurological Disease Metabolic Disease Cancer
Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of ATM protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, *p70S6K* and 4E-BP1 proteins, downregulates the expression of HIF-1α and NF-κB, and reduces the protein expression of Notch ligands Dll4 and Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating α-secretase and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of β-secretase and γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections .

HY-13787

XL-418	Akt Ribosomal S6 Kinase (RSK) GSK-3	Cancer
XL-418 is an orally active dual Akt and *p70S6K* inhibitor with IC₅₀s of 1 nM for Akt1 and 2 nM for p70S6K. XL-418 inhibits the phosphorylation of ribosomal protein S6 and GSK3β. XL-418 can be used for the study of prostate carcinoma and breast cancer .

HY-124060

PS423	PDK-1	Cancer
PS423 is a prodrug of PS210, acting as a substrate-selective inhibitor of PDK1, inhibiting the phosphorylation and activation of S6K. PS210 is a potent and selective PDK1 activator targeting the PIF binding pocket of PDK1 .

HY-13595R

Chrysophanol (Standard) Chrysophanic acid (Standard)	Reference Standards EGFR	Cancer
Chrysophanol (Standard) is the analytical standard of Chrysophanol. This product is intended for research and analytical applications. Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and *mTOR/p70S6K*.

HY-N0656AR

(+)-Usnic acid (Standard)	Reference Standards mTOR Bacterial Autophagy	Cancer
(+)-Usnic acid (Standard) is the analytical standard of (+)-Usnic acid. This product is intended for research and analytical applications. (+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of mTOR, and inhibits mTORC1/2 activity. (+)-Usnic acid inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer activity . (+)-Usnic acid possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium .

HY-P11642A

Sialorphin TFA	Enteropeptidase Aminopeptidase Opioid Receptor ERK mTOR Androgen Receptor	Inflammation/Immunology
Sialorphin TFA is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin TFA blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid receptors. Sialorphin TFA regulates the ERK/mTOR signaling pathway by inducing cell cycle arrest, enhancing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin TFA exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin TFA also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin TFA is also a copper (II) ion-binding ligand. Sialorphin TFA has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease .

HY-136765

PI3K-IN-11	PI3K	Cancer
PI3K-IN-11 (compound 13) is a PI3K inhibitor, which selectively inhibits PI3Kα, PI3Kβ, PI3K, and PI3Kδ (IC₅₀s=6.4, 13, 8, and 11 nM, respectively) over mTOR (IC₅₀=2.9 μM). PX-13-17OH is greater than 420-fold selective for PI3K in a panel of 20 lipid and protein kinases. PX-13-17OH inhibits phosphorylation of Akt and S6 kinase (S6K) in PTEN-negative U87MG cells when used at concentrations ranging from 0.03 to 1 μg/mL. It inhibits tumor growth in a U87MG mouse xenograft model when administered at doses ranging from 2.5 to 10 mg/kg.

HY-N1677R

2,6-Dimethoxy-1,4-benzoquinone (Standard)	Reference Standards Akt mTOR Bacterial Fungal AMPK	Infection Metabolic Disease Inflammation/Immunology Cancer
2,6-Dimethoxy-1,4-benzoquinone (Standard) is the analytical standard of 2,6-Dimethoxy-1,4-benzoquinone (HY-N1677). This product is intended for research and analytical applications. 2,6-Dimethoxy-1,4-benzoquinone is a 1,4-benzoquinone derivative. 2,6-Dimethoxy-1,4-benzoquinone promotes phosphorylation of AKT, S6K, mTOR, 4E-BP1, and AMPK, and attenuates mTORC1 activity as part of the AKT/mTOR pathway. 2,6-Dimethoxy-1,4-benzoquinone stimulates myoblast differentiation, increases myotube size, elevates MHC protein expression, enhances mitochondrial biogenesis, respiration, and DNA content, and increases skeletal muscle weights, fiber size, grip strength, and treadmill performance. 2,6-Dimethoxy-1,4-benzoquinone exerts anti-cancer, anti-inflammatory, anti-adipogenic, antibacterial, and antimutagenic effects, inhibits adipogenic transcription factors, nitric oxide production, skin tumor development, Magnaporthe oryzae growth, spore germination, appressorium formation, and growth of select bacterial species, induces H2O2 generation and rice defense gene expression, and reduces rice blast lesion formation. 2,6-Dimethoxy-1,4-benzoquinone can be used for the research of obesity, skin tumorigenesis, rice blast disease, and food-borne illness.

HY-117885

PF-5177624	PDK-1	Cancer
PF-5177624 is a specific and potent inhibitor of PDK1, a key enzyme in the PI3K/AKT signaling pathway that is frequently dysregulated in breast cancer. PDK1 phosphorylates AKT at T308 and other substrates, activating downstream signaling pathways that are important for tumor progression. PF-5177624 blocks IGF-1-stimulated PDK1 activity and downstream AKT and p70S6K phosphorylation, reducing cell proliferation and transformation in breast cancer cells .

HY-136700

SB-699551 free base	5-HT Receptor Akt	Neurological Disease Cancer
SB-699551 free base is a selective and brain penetrant 5-HT5A receptor antagonist with a pK_i of 8.2 nM. SB-699551 free base shows high selectivity over most other 5-HT receptor subtypes, dopamine receptors, and α1B adrenoceptor. SB-699551 free base disrupts Gαi/o-coupled and PI3K/AKT/mTOR signaling pathways, alters CREB, ATF1, AKT, PRAS40, S6K, and FOXO1 phosphorylation in breast tumor cells. SB-699551 free base can be used for the research of anxiety, breast cancer, and Alzheimer's disease .

HY-N15121

4-O-Methyl-ascochlorin	Drug Derivative Apoptosis c-Myc AMPK mTOR	Cancer
4-O-Methyl-ascochlorin (Compound MAC) is a derivative of Ascochlorin (HY-101021). 4-O-Methyl-ascochlorin can selectively induce apoptosis of K562 leukemia cells, cause G1 phase arrest and downregulate c-Myc expression. 4-O-Methyl-ascochlorin can promote the phosphorylation of AMPK and inhibit the phosphorylation of mTOR and its target proteins, including p70S6 K and 4E-BP-1. 4-O-Methyl-ascochlorin can be used for research of leukemia .

HY-181650

T133	mTOR Akt Ribosomal S6 Kinase (RSK) Apoptosis Autophagy PI3K	Cancer
T133 is an orally active ATP-competitive mTOR inhibitor with an IC₅₀ of 0.34 nM and a K_i of 0.17 nM. T133 suppresses phosphorylation of AKT, *S6K1, and 4EBP1. T133 inhibits cancer cell proliferation and migration, induces apoptosis, cell cycle arrest, and autophagy*. T133 exhibits dose-dependent antitumor efficacy in xenograft mouse models. T133 can be used for the research of cancer, such as gastric cancer and lung cancer .

HY-103100R

SB-699551 (Standard)	Reference Standards 5-HT Receptor Epigenetic Reader Domain Akt Ribosomal S6 Kinase (RSK) FOXO	Neurological Disease Cancer
SB-699551 (Standard) is the analytical standard of SB-699551 (HY-103100). This product is intended for research and analytical applications. SB-699551 is a potent and selective 5-HT5A antagonist with a K_i value of 5.1 μM. SB-699551 increases the phosphorylation levels of CREB and ATF1, and decreases the phosphorylation levels of AKT, PRAS40, P70S6K, FOXO1, and S6RP. SB-699551 improves drug-induced cognitive deficits. SB-699551 improves social withdrawal and forgetfulness. SB-699551 inhibits breast cancer.

HY-181925

FD2024	Apoptosis Pim mTOR	Cancer
FD2024 is a pan-PIM kinase inhibitor with IC₅₀ values of 0.17 nM, 1.86 nM, and 0.38 nM against PIM-1, PIM-2, and PIM-3, respectively. FD2024 induces cell apoptosis. FD2024 inhibits the phosphorylation of mTOR, *p70S6K, S6, 4EBP1, and BAD* proteins. FD2024 exhibits anti-acute myeloid leukemia activity. FD2024 can be used in studies related to acute myeloid leukemia .

HY-10514R

BX795 (Standard)	Reference Standards PDK-1 IKK Autophagy	Cancer
BX795 (Standard) is the analytical standard of BX795 (HY-10514). This product is intended for research and analytical applications. BX795 is a potent and selective inhibitor of PDK1, with an IC₅₀ of 6 nM. BX795 is also a potent and relatively specific inhibitor of TBK1 and IKKε, with an IC₅₀ of 6 and 41 nM, respectively. BX795 blocks phosphorylation of S6K1, Akt, PKCδ, and GSK3β, and has lower selectivity over PKA, PKC, c-Kit, GSK3β etc. BX795 modulates autophagy .

HY-182914

NGI-189	EGFR Akt Bcl-2 Family Apoptosis	Cancer
NGI‑189 is a selective OST‑A inhibitor. NGI‑189 inhibits the STT3A catalytic subunit of the OST complex and reduces N‑glycosylation of target glycoproteins. NGI‑189 blocks oncogenic and bypass signaling, reduces phosphorylation of EGFR, AKT, *p70S6K* and S6RP, and induces cell cycle arrest and apoptosis. NGI‑189 markedly suppresses tumor growth and induces tumor regression in non‑small cell lung cancer (NSCLC) xenograft models. NGI‑189 can be used for the research of EGFR‑mutant non‑small cell lung cancer .

HY-183307

mTOR-IN-29	mTOR STAT	Neurological Disease Cancer
mTOR-IN-29 (Compound 4k) is an mTOR inhibitor with a IC₅₀ of ~120 nM. mTOR-IN-29 inhibits mTOR kinase activity without affecting the phosphorylation of STAT3. mTOR-IN-29 acts as a cytotoxic agent against proliferating and senescent cells. mTOR-IN-29 can be used in studies related to glioblastoma .

HY-P11642

Sialorphin	ERK Androgen Receptor Opioid Receptor Enteropeptidase mTOR Aminopeptidase	Neurological Disease Inflammation/Immunology Cancer
Sialorphin is a neutral endopeptidase (NEP) and aminopeptidase N (APN) inhibitor that responds to androgen signals. Sialorphin blocks the degradation of endogenous opioid peptides and interacts with μ-, δ-, κ-opioid receptors. Sialorphin regulates the ERK/mTOR signaling pathway by inducing cell cycle arrest, enhancing ERK1/2 activity, and reducing the phosphorylation levels of mTOR, 4E-BP1, p70S6K; accordingly, Sialorphin exhibits antiproliferative activity against colorectal cancer, glioma and prostate cancer cells without cytotoxicity. In addition, Sialorphin also produces antinociceptive responses, regulates sexual behavior, relaxes corpus cavernosum smooth muscle, and alleviates experimental colitis. Sialorphin is also a copper (II) ion-binding ligand. Sialorphin has been used in mechanistic studies related to cancer, pain management and inflammatory bowel disease .

Cat. No.	Product Name	Target	Research Area